Nusano News
Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
The following is a copy of a press release issued by Clarity Pharmaceuticals on April 17, 2025 in Australia. Minor edits have been made in this copy to account for...
Nusano to Participate in October Investor Conferences
Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced that senior management will participate in the following investor conferences in October.
Nusano Appoints Industry Expert Alexandre Gibim as Chief Operations Officer
Nusano, Inc. has appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer (COO). Gibim will be responsible for enabling and scaling Nusano’s business functions to create a reliable domestic and global supply of medical radioisotopes, the active pharmaceutical ingredients (APIs) at the core of next-generation cancer therapeutics.
Video Replay: Unlocking the Next $20-30B Market Opportunity in Oncology: Radioisotope Production & Applications
With many now expecting radiopharmaceuticals to grow into a $20-30 billion market, investors are increasingly looking at the obstacles and opportunities for suppliers and drugmakers in this space. To advance these discussions, on Friday, May 12, 2023, Nusano and...
Nusano to Participate in Isotope and Radiopharmaceutical Conferences
Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, is participating in two conferences in July 2023.
Nusano and PharmaLogic Announce Collaboration to Enable Next Generation Radiotherapeutics Development
Nusano and PharmaLogic will collaborate to advance the development of radiopharmaceuticals for diagnostic and therapeutic applications.
Nusano Announces In-House Stable Isotope Program Led by Renowned Physicist Sarko Cherekdjian
Nusano is creating an in-house stable isotope program to enhance the company’s medical radioisotope production capabilities and decrease dependence on foreign supply chains.
Nusano to Participate in the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day
Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will participate in a fireside chat at the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day in New York City on Monday, May 15, 2023.
Nusano to Host Key Opinion Leader Webinar on Isotope Production and Applications for Oncology Radio-pharmaceuticals
Nusano is hosting a virtual Key Opinion Leader (KOL) event on Friday, May 12, 2023 at 10 a.m. EST. The event will highlight the rapidly expanding and critically undersupplied medical radioisotopes market, including current limitations and what must be overcome to improve patient care and unlock market potential.
Nusano to Present Production Capabilities to European Radiopharmaceuticals Working Group
Nusano will present an overview of the company’s breakthrough production platform to the European Cooperation in Science and Technology (COST) Astatine-211 Working Group on May 4, 2023. Presentation materials will be available on the company’s website following the event.
Nusano Co-Founder Dr. Howard Lewin to Participate in Truist Securities Virtual Radiopharmaceuticals Event
Nusano’s Dr. Howard Lewin will take part in a virtual event hosted by Truist Securities on Friday, April 21, 2023, at 3:30 p.m. Eastern.
BLOG Posts
U.S. investing in domestic isotope supply
Department of Energy Secretary Jennifer Granholm breaks ground on facility to provide radioisotopes vital to national security, research and health care.
University of Missouri responds to global radioisotope shortage
An unplanned production outage in Europe poses a threat to radioisotope supplies worldwide.
Reuters: EU may face shortage of key materials for diagnostics, cancer treatments
European officials are warning of a potential shortage of medical radioisotopes needed for advanced health care and imaging procedures.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates